Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2017)
  • Fellowship: Texas Children's Hospital BMT Fellowship Program (2017) TX
  • Fellowship: UC Irvine Pediatric Hematology/Oncology Program (2016) CA
  • Board Certification: American Board of Pediatrics, Pediatrics (2013)
  • Residency: UC Davis Dept of Pediatrics Residency Program (2013) CA
  • Medical Education: Wake Forest University Office of the Registrar (2010) NC

Contact

  • Academic
    tdjohn10@stanford.edu
    University - Academic staff Department: Pediatrics - Ped Stem Cell Transplantation Position: Clinical Associate Professor
    • 750 Welch Rd Ste 200/224
    • Mc5798
    • Palo Alto,  California  94304-1507 
  • Clinical (Primary)  Pediatric Stem Cell Transplantation 1000 Welch Rd Ste 301 MC 5208 Stanford, CA 94305 (650) 723-5231 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5798

All Publications

  • Incremental Eligibility Criteria for the BMT CTN 1507 Haploidentical Trial for Children with Sickle Cell Disease. Blood advances John, T. D., Walters, M. C., Rangarajan, H. G., Rahim, M. Q., McKinney, C. M., Bollard, C. M., Abusin, G., Eapen, M., Kassim, A. A., DeBaun, M. R. 2024

    Abstract

    The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1507 leadership and the Data Safety Monitoring Board (DSMB) established incremental entry criteria for children aged 5-14.99 years with sickle cell disease (SCD) enrolling on a phase 2 trial of HLA-haploidentical hematopoietic stem cell transplantation (clinicaltrials.gov #NCT032635590). First, enrollment was limited to overt stroke in the first 10 participants (Stage 4). Subsequently, the DSMB reviewed the interim results and expanded eligibility to include children with silent cerebral infarcts or abnormal transcranial Doppler velocities with magnetic resonance angiography-defined cerebral vasculopathy (Stage 3). A third cohort was enrolled after the DSMB reviewed the clinical outcomes in these cumulative initial enrollments (n=18). Additions to the entry criteria included non-neurologic morbidities (Stage 2). Eligibility criteria included: a) life-threatening acute chest syndrome requiring exchange transfusion, b) right heart catheterization confirmed pulmonary hypertension, c) persistent systemic hypertension despite maximum medical therapy, d) acute pain despite maximum medical therapy in the absence of psychosocial factors and unmanaged asthma after adjudication, or e) 2 major priapism episodes in 12 months or 3 in 24 months. Children with SCD who did not meet the criteria for stages 4, 3, and 2 were not eligible. For the first time, we introduce a staged strategy to eligibility for a curative therapy trial for children with SCD concordant with 45 CFR ยง 46.405(b). The research governance-mandated eligibility strategy used within the BMT CTN 1507 phase 2 study may apply to future pediatric SCD curative therapy trials.

    View details for DOI 10.1182/bloodadvances.2024014078

    View details for PubMedID 39374573

  • Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease. The Lancet. Haematology Sharma, A., John, T. D. 2024

    View details for DOI 10.1016/S2352-3026(24)00175-3

    View details for PubMedID 38964356

  • Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy John, T. D., Maron, G., Abraham, A., Bertaina, A., Bhoopalan, S. V., Bidgoli, A., Bonfim, C., Coleman, Z., DeZern, A., Li, J., Louis, C., Oved, J., Pavel-Dinu, M., Purtill, D., Ruggeri, A., Russell, A., Wynn, R., Boelens, J. J., Prockop, S., Sharma, A. 2024

    Abstract

    There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.

    View details for DOI 10.1016/j.jcyt.2024.02.005

    View details for PubMedID 38483362

  • Red Cell Rheology and Blood Viscosity in Pediatric Individuals Having Received Allogenic Hematopoietic Stem Cell Transplantation or Ex Vivo Autologous Gene Therapy for Sickle Cell Disease Patel, A. P., Kanne, C. K., Stenger, E. O., John, T. D., Sheehan, V. A. AMER SOC HEMATOLOGY. 2023

    View details for DOI 10.1182/blood-2023-188045

    View details for Web of Science ID 001159306704100

  • Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study John, T. D., Chellapandian, D., Shah, R., Gillespie, S., Liu, K., Xiang, Y., Bhatia, M., Chaudhury, S., Eckrich, M. J., Guilcher, G. T., Jaroscak, J., Kasow, K. A., Krajewski, J., Ngwube, A. I., Olson, T. S., Rangarajan, H. G., Horan, J. T., Krishnamurti, L., Shenoy, S., Abraham, A., Stenger, E. AMER SOC HEMATOLOGY. 2023

    View details for DOI 10.1182/blood-2023-182532

    View details for Web of Science ID 001159900800105

  • Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study Stenger, E., John, T. D., Chellapandian, D., Shah, R., Gillespie, S., Xiang, Y., Liu, K., Bhatia, M., Guilcher, G. T., Jaroscak, J., Kasow, K. A., Krajewski, J., Ngwube, A. I., Rangarajan, H. G., Horan, J. T., Krishnamurti, L., Shenoy, S., Abraham, A. AMER SOC HEMATOLOGY. 2023

    View details for DOI 10.1182/blood-2023188514

    View details for Web of Science ID 001159900800156